Some highlights:
"We have initiated interactions with regulatory authorities to continue our efforts to bring ataluren to patients."
"These results suggest for the first time that a therapy which addresses the underlying cause of the disease can slow the loss of walking ability, the primary clinical symptom of dystrophinopathy"
"- 29.7 meter average change in 6-minute walk distance compared to placebo at 48 weeks - - Safety results show ataluren was generally well tolerated - - Data to be the basis of interactions with regulatory authorities "
They are finally moving ahead with submitting to the FDA! I don't know how long that will take, but since it's on the "fast track" (which isn't fast enough in my opinion, but faster than other meds I suppose) hopefully Pat Furlong was right when she said next spring.
-
No comments:
Post a Comment